iNtRON Biotechnology Inc - Asset Resilience Ratio

Latest as of September 2025: 10.90%

iNtRON Biotechnology Inc (048530) has an Asset Resilience Ratio of 10.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 048530 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩8.58 Billion

≈ $5.81 Million USD Cash + Short-term Investments

Total Assets

₩78.70 Billion

≈ $53.34 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how iNtRON Biotechnology Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see iNtRON Biotechnology Inc assets under control.

Liquid Assets Composition Over Time

This chart breaks down iNtRON Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 048530 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩8.58 Billion	10.9%
Total Liquid Assets	₩8.58 Billion	10.90%

Asset Resilience Insights

Moderate Liquidity: iNtRON Biotechnology Inc has 10.90% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

iNtRON Biotechnology Inc Industry Peers by Asset Resilience Ratio

Compare iNtRON Biotechnology Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for iNtRON Biotechnology Inc (2012–2024)

The table below shows the annual Asset Resilience Ratio data for iNtRON Biotechnology Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	17.85%	₩15.42 Billion ≈ $10.45 Million	₩86.37 Billion ≈ $58.53 Million	-40.14pp
2023-12-31	57.99%	₩57.18 Billion ≈ $38.75 Million	₩98.61 Billion ≈ $66.83 Million	+24.40pp
2022-12-31	33.59%	₩47.35 Billion ≈ $32.09 Million	₩140.96 Billion ≈ $95.53 Million	-20.85pp
2021-12-31	54.44%	₩83.49 Billion ≈ $56.58 Million	₩153.37 Billion ≈ $103.93 Million	-11.37pp
2020-12-31	65.81%	₩66.16 Billion ≈ $44.84 Million	₩100.54 Billion ≈ $68.13 Million	+2.50pp
2019-12-31	63.32%	₩56.37 Billion ≈ $38.20 Million	₩89.03 Billion ≈ $60.34 Million	+24.70pp
2018-12-31	38.62%	₩21.16 Billion ≈ $14.34 Million	₩54.80 Billion ≈ $37.13 Million	-3.16pp
2017-12-31	41.77%	₩19.06 Billion ≈ $12.92 Million	₩45.63 Billion ≈ $30.92 Million	+2.51pp
2016-12-31	39.26%	₩23.40 Billion ≈ $15.86 Million	₩59.61 Billion ≈ $40.39 Million	+29.03pp
2015-12-31	10.23%	₩4.13 Billion ≈ $2.80 Million	₩40.37 Billion ≈ $27.36 Million	-3.92pp
2012-12-31	14.15%	₩2.78 Billion ≈ $1.88 Million	₩19.64 Billion ≈ $13.31 Million	--

pp = percentage points

About iNtRON Biotechnology Inc

KQ:048530 Korea Biotechnology

Market Cap

$60.63 Million

₩89.47 Billion KRW

Market Cap Rank

#21248 Global

#1235 in Korea

Share Price

₩2830.00

Change (1 day)

-4.07%

52-Week Range

₩2330.00 - ₩6650.00

All Time High

₩46250.00